Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective - Concepedia

Concepedia

Publication | Open Access

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

DOI Full Paper Access

40

Citations

36

References

2015

Year

M. Charokopou, Phil McEwan, Steven Lister, Luke Callan, Klas Bergenheim, Keith Tolley, Rolf J. Postema, R. Townsend, M. Roudaut

BMC Health Services Research

References

	Year	Citations

Page 1